This article is provided for educational and informational purposes only. It does not constitute legal, financial, or tax advice, and no attorney-client relationship is formed by reading it. Laws, regulations, official guidance, and related information vary by jurisdiction, change frequently, and may have changed or become outdated since the publication date. Always verify current information with authoritative sources and consult a qualified professional about your specific circumstances. The author and publisher assume no liability for actions taken based on this information.
Key Facts
- Federal level: The 2018 Farm Bill removed qualifying hemp from the Controlled Substances Act definition of marijuana but preserved FDA authority over hemp-derived products.
- Federal level: Hemp status does not by itself make a CBD food, supplement, drug, cosmetic, or animal product lawful under the Federal Food, Drug, and Cosmetic Act.
- Federal level: FDA continues to conclude that CBD products are excluded from the dietary-supplement definition under the drug-exclusion provision.
- Federal level: Epidiolex remains the only FDA-approved drug product containing CBD; disease claims can cause other CBD products to be regulated as unapproved drugs.
- Federal level: A narrower federal hemp definition enacted in 2025 is scheduled to take effect November 12, 2026, after this article’s publication date.
The phrase “FDA CBD 2018” points to two separate events. FDA approved Epidiolex, a prescription CBD drug, in June 2018, and Congress enacted the 2018 Farm Bill that December. Neither event generally authorized CBD as an ingredient in conventional food or dietary supplements.
The Farm Bill changed federal controlled-substance treatment for qualifying hemp. It expressly left FDA’s authority under the Federal Food, Drug, and Cosmetic Act and Public Health Service Act intact.
What the 2018 Farm Bill changed
The 2018 law defined hemp as Cannabis sativa L. and its derivatives with no more than 0.3 percent delta-9 THC on a dry-weight basis. It excluded that hemp from the Controlled Substances Act’s marijuana definition and created a federal agricultural framework for hemp production.
That change concerned controlled-substance and agricultural law. A hemp-derived ingredient still had to satisfy every law applicable to its product category, including FDA rules for foods, supplements, drugs, cosmetics, and animal products.
CBD in foods and dietary supplements
FDA states that introducing food with added CBD into interstate commerce is prohibited under the FD&C Act’s drug-exclusion rule. FDA has not issued a regulation creating an exception for CBD in conventional food.
FDA also concludes that CBD products are excluded from the statutory definition of a dietary supplement because CBD was the subject of substantial public drug investigations and is an active ingredient in an approved drug. The statute contains a prior-marketing exception, but FDA says available evidence does not establish it for CBD.
In January 2023, FDA denied citizen petitions seeking a rule for CBD supplements. The agency concluded that existing food and supplement pathways were not appropriate for CBD and said a new regulatory pathway would require congressional action.
Drug claims trigger a different pathway
A product intended to diagnose, cure, mitigate, treat, or prevent disease is a drug under federal law. New drugs generally require FDA approval before interstate marketing unless a specific lawful pathway applies.
Epidiolex is the only FDA-approved drug product containing CBD. Its approval for specified seizure disorders does not approve other CBD products, dosages, manufacturing methods, or therapeutic claims.
FDA warning letters commonly address unapproved disease claims, misbranding, and products marketed in prohibited categories. The fact that a product is widely sold does not establish FDA approval or federal compliance.
Cosmetics and animal products
Cosmetics generally do not require premarket ingredient approval, except for most color additives, but they may not be adulterated or misbranded. Therapeutic claims can change a cosmetic’s regulatory classification to a drug.
FDA has not approved CBD as an animal-food additive and has expressed concern about exposure through meat, milk, and eggs. Animal products making treatment claims can also be unapproved new animal drugs.
The federal hemp definition changes again in November 2026
As of August 8, 2026, the 2018 delta-9 THC definition remains operative. Public Law 119-37 enacted a narrower definition based on total tetrahydrocannabinols and exclusions for specified cannabinoid products, effective 365 days after November 12, 2025.
The scheduled effective date is November 12, 2026. That future controlled-substance change does not erase the separate FDA rules that already apply to foods, supplements, drugs, cosmetics, or animal products.
State law remains a separate layer
States may impose their own manufacturing, testing, labeling, age, retail, or product restrictions. State permission does not override federal FDA requirements, and federal hemp status does not guarantee compliance with a particular state’s law.
The broader concept of a federal regulation helps explain why statutory changes and agency product rules must be read together. For a specific CBD product, its ingredients, intended use, claims, route of administration, and jurisdiction all matter.
